The DELIVER Trial

Key messages

• HF with preserved EF is under recognised in both diabetes and cardiology communities. Patients with both HF and diabetes are at much higher risk of hospitalisation and CV death than patients without diabetes.
• The DELIVER trial reported that dapagliflozin reduced the risk of worsening HF and CV death by 18% in patients with HF and mildly reduced EF and in patients with HF and preserved EF.
• Patients with diabetes, HF and reduced EF, HF and preserved EF, and hospitalised for acute HF benefitted from using SGLT2 inhibitors; more patient populations could also benefit from SGLT2 inhibitors and must be evaluated.